Date: 2016-06-21
Type of information: Nomination
Compound:
Company: Keryx Biopharmaceuticals (USA - NY)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On June 21, 2016, Keryx Biopharmaceuticals announced that Michael Heffernan and Jodie Morrison joined its board of directors, effective immediately. These new appointments bring the size of the company's board to eight members and reflect achievement of Keryx's commitment to add further complementary expertise to its Board. Michael Heffernan is founder, president, and chief executive officer of Collegium Pharmaceutical , a publicly traded drug development company targeting chronic pain. Jodie Morrison is president and chief executive officer of Tokai Pharmaceuticals , a publicly traded biopharmaceutical company focused on developing and commercializing innovative medicines for hormonally driven diseases, with an investigational medicine for prostate cancer in Phase 3 development. Michael will serve on Keryx's compensation committee and its nominating and governance committee. Jodie will serve on the company's audit committee and research and development committee.
Financial terms:
Latest news:
